Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment.
Ontology highlight
ABSTRACT: Cancer cells take up amino acids from the extracellular space to drive cell proliferation and viability. Similar mechanisms are applied by immune cells, resulting in the competition between conventional T cells, or indeed chimeric antigen receptor (CAR) T cells and tumor cells, for the limited availability of amino acids within the environment. We demonstrate that T cells can be re-engineered to express SLC7A5 or SLC7A11 transmembrane amino acid transporters alongside CARs. Transporter modifications increase CAR T-cell proliferation under low tryptophan or cystine conditions with no loss of CAR cytotoxicity or increased exhaustion. Transcriptomic and phenotypic analysis reveals that downstream, SLC7A5/SLC7A11-modified CAR T cells upregulate intracellular arginase expression and activity. I
SUBMITTER: Panetti S
PROVIDER: S-EPMC10182289 | biostudies-literature | 2023 May
REPOSITORIES: biostudies-literature
ACCESS DATA